NKTR | tickerfilter.com

Fundamental analysis

52%

Profitability 0%

Dept financing 50%

Liquidity 68%

Performance 100%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

3.42%

1 Month

90.72%

3 Months

23.43%

6 Months

59.49%

1 Year

7,952.39%

2 Year

7,298.49%

Key data

Stock price

$70.70

P/E Ratio

0.00

DAY RANGE

$70.50 - $72.98

EPS

-$5.02

52 WEEK RANGE

$0.43 - $75.67

52 WEEK CHANGE

$8,521.95

MARKET CAP

1.082 B

YIELD

N/A

SHARES OUTSTANDING

20.342 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-08-2025

BETA

2.59

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,045,664

AVERAGE 30 VOLUME

$1,740,880

Company detail

CEO: Howard W. Robin
Region: US
Website: nektar.com
Employees: 220
IPO year: 1994

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinomas of the head and neck, and adjuvant melanoma. It is also developing NKTR-358, a cytokine Treg stimulant, in phase 2 clinical trial for the treatment of systemic lupus erythematosus

NKTR - NEKTAR THERAPEUTICS